In our simulations, A3G-augmented stem cell therapy (A3G-SCT) is introduced on day 100 after initial infection by changing the production of uninfected CD4+ T cells in thymus to generate both WT and A3G-augmented CD4+ T cells with the ratio of 1-f:f. Here, CD4 is linked to infection.